Search

Your search keyword '"Castro, Daniela V."' showing total 48 results
Start Over Author "Castro, Daniela V."
48 results on '"Castro, Daniela V."'

1. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research

Author

Ebrahimi, Hedyeh, Castro, Daniela V., Feng, Matthew I., Prajapati, Sweta R., Lee, Kyle O., Chan, Elyse H., Paul, Trishita, Sehgal, Ishaan, Patel, Jalen, Li, Xiaochan, Zengin, Zeynep B., Meza, Luis, Mercier, Benjamin D., Hsu, JoAnn, Govindarajan, Ameish, Chawla, Neal, Dizman, Nazli, Bergerot, Cristiane D., Rock, Adam, Liu, Sandy, Tripathi, Abhishek, Dorff, Tanya, Pal, Sumanta K., and Chehrazi-Raffle, Alexander

Published
2023
Full Text
View/download PDF

2. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma

Author

Dizman, Nazli, Govindarajan, Ameish, Zengin, Zeynep B., Meza, Luis, Tripathi, Nishita, Sayegh, Nicolas, Castro, Daniela V., Chan, Elyse H., Lee, Kyle O., Prajapati, Sweta, Feng, Matthew, Loo, Vivian, Pace, Makala, O'Brien, Shea, Bailey, Erin, Barragan-Carrillo, Regina, Chehrazi-Raffle, Alex, Hsu, JoAnn, Li, Xiaochen, Agarwal, Neeraj, and Pal, Sumanta K.

Published
2023
Full Text
View/download PDF

3. Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity

Author

Park, Sang Ho, Siddiqi, Haley, Castro, Daniela V, De Angelis, Anna A, Oom, Aaron L, Stoneham, Charlotte A, Lewinski, Mary K, Clark, Alex E, Croker, Ben A, Carlin, Aaron F, Guatelli, John, and Opella, Stanley J

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Infectious Diseases, Biodefense, Vaccine Related, Prevention, Lung, Emerging Infectious Diseases, Pneumonia, Underpinning research, 2.2 Factors relating to the physical environment, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 1.1 Normal biological development and functioning, Aetiology, Infection, Amiloride, Animals, Antiviral Agents, Binding Sites, COVID-19, Chlorocebus aethiops, Coronavirus Envelope Proteins, Humans, Ion Channels, Nuclear Magnetic Resonance, Biomolecular, Protein Binding, Protein Conformation, Protein Domains, SARS-CoV-2, Vero Cells, Virus Assembly, COVID-19 Drug Treatment, Microbiology, Immunology, Medical Microbiology, Virology, Medical microbiology
Abstract

SARS-CoV-2 is the novel coronavirus that is the causative agent of COVID-19, a sometimes-lethal respiratory infection responsible for a world-wide pandemic. The envelope (E) protein, one of four structural proteins encoded in the viral genome, is a 75-residue integral membrane protein whose transmembrane domain exhibits ion channel activity and whose cytoplasmic domain participates in protein-protein interactions. These activities contribute to several aspects of the viral replication-cycle, including virion assembly, budding, release, and pathogenesis. Here, we describe the structure and dynamics of full-length SARS-CoV-2 E protein in hexadecylphosphocholine micelles by NMR spectroscopy. We also characterized its interactions with four putative ion channel inhibitors. The chemical shift index and dipolar wave plots establish that E protein consists of a long transmembrane helix (residues 8-43) and a short cytoplasmic helix (residues 53-60) connected by a complex linker that exhibits some internal mobility. The conformations of the N-terminal transmembrane domain and the C-terminal cytoplasmic domain are unaffected by truncation from the intact protein. The chemical shift perturbations of E protein spectra induced by the addition of the inhibitors demonstrate that the N-terminal region (residues 6-18) is the principal binding site. The binding affinity of the inhibitors to E protein in micelles correlates with their antiviral potency in Vero E6 cells: HMA ≈ EIPA > DMA >> Amiloride, suggesting that bulky hydrophobic groups in the 5' position of the amiloride pyrazine ring play essential roles in binding to E protein and in antiviral activity. An N15A mutation increased the production of virus-like particles, induced significant chemical shift changes from residues in the inhibitor binding site, and abolished HMA binding, suggesting that Asn15 plays a key role in maintaining the protein conformation near the binding site. These studies provide the foundation for complete structure determination of E protein and for structure-based drug discovery targeting this protein.

Published
2021

5. Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.

Author

Bergerot, Cristiane Decat, Philip, Errol J., Malhotra, Jasnoor, Bergerot, Paulo Gustavo, Castro, Daniela V., Govindarajan, Ameish, Salgia, Sabrina, Salgia, Meghan, Salgia, Nicholas, Hsu, JoAnn, Meza, Luis, Zengin, Zeynep B., Liu, Sandy, Chehrazi‐Raffle, Alex, Tripathi, Abhishek, Dorff, Tanya, and Pal, Sumanta

Abstract

We sought to determine racial and ethnic differences in perceptions (quality of communication, expectations, and concerns) of germline or somatic DNA sequencing (genomic profiling). Patients with prostate, urothelial, or kidney cancer were surveyed using a questionnaire that assessed previous experience, beliefs, expectations, and concerns regarding genomic profiling. Descriptive statistics and chi‐square tests were used to identify factors associated with patients' perceptions of genomic profiling. A total of 150 consecutive patients were enrolled. The majority were male (74%) with a mean age of 68 years old. Most patients underwent somatic testing (54%), 24% undertook germline testing, and 21% undertook both tests. Significant differences were found across racial and/or ethnicity concerning factors that could have influenced patients' decision to pursue genomic profiling, including ability to guide the type of treatment (White: 54.1% vs. other ethnic groups: 43.9%, p = 0.04) and potential to improve treatment response (White: 10.1% vs. other ethnic groups: 22.0%, p = 0.04). Other ethnic group of patients were more concerned about learning that the cancer was less treatable or aggressive (43.8% vs. 27.7%, p = 0.01) and anxious about what would be learnt from genomic profiling (34.4% vs. 21.3, p = 0.01) as compared to White patients. Our findings reinforce the importance of developing culturally tailored education to help patients participate actively in decisions about genomic profiling. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.

Author

Castro, Daniela V., Prajapati, Sweta R., Feng, Matthew I., Chan, Elyse H., Lee, Kyle O., Paul, Trishita, Sehgal, Ishaan, Patel, Jalen, Li, Xiaochen, Zengin, Zeynep B., Ebrahimi, Hedyeh, Govindarajan, Ameish, Meza, Luis, Mercier, Benjamin D., Chawla, Neal S., Dizman, Nazli, Philip, Errol J., Hsu, JoAnn, Bergerot, Cristiane D., and Chehrazi‐Raffle, Alex

Subjects
*RENAL cell carcinoma, *HEPATITIS C virus, *HEPATITIS B virus, *HIV, *HIV infections
Abstract

Objectives: To characterise the restrictiveness of eligibility criteria in contemporary renal cell carcinoma (RCC) trials, using recommendations from the American Society of Clinical Oncology (ASCO)‐Friends of Cancer Research (FCR) initiative. Methods: vPhase I–III trials assessing systemic therapies in patients with RCC starting between 30 June 2012 and 30 June 2022 were identified. Eligibility criteria regarding brain metastases, prior or concurrent malignancies, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, and human immunodeficiency virus (HIV) infection were identified and stratified into three groups: exclusion, conditional inclusion, and not reported. Descriptive statistics were used to determine the frequency of eligibility criteria. Fisher's exact test or chi‐square test were used to calculate their associations with certain trial characteristics. Results: A total of 423 RCC trials were initially identified of which 112 (26.5%) had sufficient accessible information. Exclusion of patients with HIV infection, HBV/HCV infection, brain metastases, and prior or concurrent malignancies were reported in 74.1%, 53.6%, 33.0%, and 8.0% of trials, respectively. In the context of HIV and HBV/HCV infection, patients were largely excluded from trials evaluating immunotherapy (94.4% and 77.8%, respectively). In addition, brain metastases were excluded in trials assessing targeted therapy (36.4%), combined therapy (33.3%), and immunotherapy (22.2%). Exclusion of patients with prior or concurrent malignancies was less frequently reported, accounting for 9.1%, 8.3%, and 5.6% targeted therapy, combined therapy and immunotherapy trials, respectively. Conclusion: A substantial proportion of RCC trials utilise restrictive eligibility criteria, excluding patients with fairly prevalent comorbidities. Implementing the ASCO‐FCR recommendations will ensure resulting data are more inclusive and aligned with patient populations in the real‐world. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).

Author

Barragan-Carrillo, Regina, Chawla, Neal Shiv, Salgia, Nicholas, Meza, Luis A, Zengin, Zeynep Busra, Li, Xiaochen, Dizman, Nazli, Ebrahimi, Hedyeh, Hsu, Joann, Castro, Daniela V., Mercier, Benjamin D., Dorff, Tanya B., Tripathi, Abhishek, Bergerot, Cristiane Decat, Bergerot, Paulo Gustavo, Chehrazi-Raffle, Alex, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

8. Adherence to American Society of Clinical Oncology (ASCO) language of respect (LoR) guidelines in ASCO Annual Meeting prostate cancer (PCa) abstracts.

Author

Barragan-Carrillo, Regina, Wong, Megan Hoikei, Dizman, Nazli, Castro, Daniela V., Mercier, Benjamin D., Li, Xiaochen, Faridi, Amber, Goud, Jaya, Paul, Trishita, Chan, Ethan, Dukkipati, Akasha, Paul, Teebro, Zugman, Miguel, Ebrahimi, Hedyeh, Dorff, Tanya B., Chehrazi-Raffle, Alex, Pal, Sumanta Kumar, Florez, Narjust, and Prowell, Tatiana Michelle

Published
2024
Full Text
View/download PDF

9. Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract.

Author

Chawla, Neal Shiv, Mercier, Benjamin D., Govindarajan, Ameish, Li, Xiaochen, Castro, Daniela V., Ebrahimi, Hedyeh, Barragan-Carrillo, Regina, Zang, Peter D., LeVee, Alexis Ann, Dizman, Nazli, Hsu, Joann, Meza, Luis A, Zengin, Zeynep Busra, Salgia, Nicholas, Chehrazi-Raffle, Alex, Dorff, Tanya B., Pal, Sumanta Kumar, and Tripathi, Abhishek

Published
2024
Full Text
View/download PDF

10. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).

Author

Mercier, Benjamin D., Tripathi, Nishita, Govindarajan, Ameish, Gebrael, Georges, Narang, Arshit, Li, Xiaochen, Castro, Daniela V., Chehrazi-Raffle, Alex, Dizman, Nazli, Ebrahimi, Hedyeh, Chawla, Neal Shiv, Hsu, Joann, Bergerot, Cristiane Decat, Barragan-Carrillo, Regina, Zengin, Zeynep Busra, Meza, Luis A, Pal, Sumanta Kumar, Agarwal, Neeraj, and Tripathi, Abhishek

Published
2024
Full Text
View/download PDF

11. Adherence to ASCO Language of Respect (LoR) guidelines in urothelial carcinoma (UC) abstracts at the 2023 ASCO Annual Meeting.

Author

Castro, Daniela V., Mercier, Benjamin D., Zugman, Miguel, Li, Xiaochen, Barragan-Carrillo, Regina, Wong, Megan Hoikei, Chan, Ethan, Faridi, Amber, Goud, Jaya, Paul, Trishita, Dukkipati, Akasha, Patel, Jalen, Paul, Teebro, Ebrahimi, Hedyeh, Chawla, Neal Shiv, Chehrazi-Raffle, Alex, Prowell, Tatiana Michelle, Florez, Narjust, Dizman, Nazli, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

12. Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.

Author

Ebrahimi, Hedyeh, Meza, Luis A, Lee, Keehoon, Malhotra, Jasnoor, Alcantara, Marice, Zengin, Zeynep Busra, Dizman, Nazli, Hsu, Joann, Llamas-Quitiquit, Marian, Castro, Daniela V., Mercier, Benjamin D., Barragan-Carrillo, Regina, Chawla, Neal Shiv, Li, Xiaochen, Liu, Sandy, Chehrazi-Raffle, Alex, Dorff, Tanya B., Frankel, Paul Henry, Tripathi, Abhishek, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

13. From guidelines to accountability: Examining adherence to ASCO Language of Respect in renal cell carcinoma (RCC) abstracts.

Author

Dizman, Nazli, Castro, Daniela V., Mercier, Benjamin D., Li, Xiaochen, Barragan-Carrillo, Regina, Wong, Megan Hoikei, Chan, Ethan, Dukkipati, Akasha, Paul, Teebro, Faridi, Amber, Patel, Jalen, Goud, Jaya, Paul, Trishita, Zugman, Miguel, Ebrahimi, Hedyeh, Chehrazi-Raffle, Alex, Dorff, Tanya B., Prowell, Tatiana Michelle, Pal, Sumanta Kumar, and Florez, Narjust

Published
2024
Full Text
View/download PDF

14. Association between thymectomy and incidence of renal cell carcinoma (RCC).

Author

Barragan-Carrillo, Regina, Ebrahimi, Hedyeh, Chawla, Neal Shiv, Salgia, Nicholas, Castro, Daniela V., Chehrazi-Raffle, Alex, Dizman, Nazli, Hsu, Joann, Meza, Luis A, Zengin, Zeynep Busra, LeVee, Alexis Ann, Tripathi, Abhishek, Dorff, Tanya B., Bergerot, Cristiane Decat, Bergerot, Paulo Gustavo, Eilber, Karyn, Dallas, Kai, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

15. Development of a patient-centered health-related quality of life (HRQOL) measure for metastatic renal cell carcinoma (mRCC): A three-phase study.

Author

Bergerot, Cristiane Decat, Castro, Daniela V., Bergerot, Paulo Gustavo, Mercier, Benjamin D., Nally, Elizabeth, Ali, Adil A., Philip, Errol James, Buso, Murilo, Hutson, Thomas E., Grünwald, Viktor, Bex, Axel, Psutka, Sarah P., Rini, Brian I., Plimack, Elizabeth R., Master, Viraj A., Albiges, Laurence, Choueiri, Toni K., Pal, Sumanta Kumar, and Powles, Thomas

Published
2024
Full Text
View/download PDF

16. Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer

Author

Bergerot, Cristiane Decat, primary, Philip, Errol J., additional, Malhotra, Jasnoor, additional, Bergerot, Paulo Gustavo, additional, Castro, Daniela V., additional, Govindarajan, Ameish, additional, Salgia, Sabrina, additional, Salgia, Meghan, additional, Salgia, Nicholas, additional, Hsu, JoAnn, additional, Meza, Luis, additional, Zengin, Zeynep B., additional, Liu, Sandy, additional, Chehrazi‐Raffle, Alex, additional, Tripathi, Abhishek, additional, Dorff, Tanya, additional, and Pal, Sumanta, additional

Published
2023
Full Text
View/download PDF

17. CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)

Author

Ebrahimi, Hedyeh, primary, Lu, Kun-Han, additional, Castro, Daniela V, additional, Mercier, Benjamin D, additional, Dizman, Nazli, additional, Barragan-Carrillo, Regina, additional, Govindarajan, Ameish, additional, Meza, Luis, additional, Chawla, Neal S, additional, Hsu, JoAnn, additional, Chehrazi-Raffle, Alexander, additional, Tripathi, Abhishek, additional, Liu, Sandy, additional, Dorff, Tanya B, additional, Wah Wong, Chi, additional, Pal, Sumanta K, additional, and Zengin, Zeynep B, additional

Published
2023
Full Text
View/download PDF

18. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles

Author

Govindarajan, Ameish, primary, Salgia, Nicholas J., additional, Li, Haiqing, additional, Castro, Daniela V., additional, Mirzapoiazova, Tamara, additional, Armstrong, Brian, additional, Zhao, Dan, additional, Mercier, Benjamin D., additional, Dizman, Nazli, additional, Chawla, Neal, additional, Zengin, Zeynep, additional, Meza, Luis, additional, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Chehrazi-Raffle, Alex, additional, Tripathi, Abhishek, additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

19. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy

Author

Castro, Daniela V., primary, Prajapati, Sweta R., additional, Feng, Matthew I., additional, Chan, Elyse H., additional, Lee, Kyle O., additional, Paul, Trishita, additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, Li, Xiaochen, additional, Zengin, Zeynep B., additional, Ebrahimi, Hedyeh, additional, Govindarajan, Ameish, additional, Meza, Luis, additional, Mercier, Benjamin D., additional, Chawla, Neal S., additional, Dizman, Nazli, additional, Philip, Errol J., additional, Hsu, JoAnn, additional, Bergerot, Cristiane D., additional, Chehrazi‐Raffle, Alex, additional, Rock, Adam, additional, Liu, Sandy, additional, Tripathi, Abhishek, additional, Dorff, Tanya B., additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

20. Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19

Author

Bergerot, Cristiane Decat, primary, Malhotra, Jasnoor, additional, Bergerot, Paulo, additional, Philip, Errol J, additional, Castro, Daniela V, additional, Hsu, JoAnn, additional, Mota, Augusto Cesar de Andrade, additional, Cardoso de Azeredo, Andressa, additional, Neto, João Nunes de Matos, additional, Hutson, Thomas, additional, Grünwald, Viktor, additional, Bex, Axel, additional, Psutka, Sarah P, additional, Rini, Brian, additional, Plimack, Elizabeth R, additional, Master, Viraj, additional, Albiges, Laurence, additional, Choueiri, Toni K, additional, Pal, Sumanta, additional, and Powles, Thomas, additional

Published
2023
Full Text
View/download PDF

21. Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations.

Author

Prajapati, Sweta R., primary, Feng, Matthew I., additional, Castro, Daniela V., additional, Lee, Kyle O., additional, Chan, Elyse H., additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, O'Dell, Anna, additional, Zengin, Zeynep Busra, additional, Li, Xiaochen, additional, Chehrazi-Raffle, Alex, additional, Dizman, Nazli, additional, Tripathi, Abhishek, additional, Rock, Adam, additional, Liu, Sandy, additional, Mercier, Benjamin D., additional, Meza, Luis A, additional, Philip, Errol James, additional, Dorff, Tanya B., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

22. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).

Author

Leong, Sally, primary, Ali, Sana, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Dizman, Nazli, additional, Ebrahimi, Hedyeh, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Li, Xiaochen, additional, Kim, Tane, additional, Melamed, Sam, additional, Onyshchenko, Mykola, additional, Pal, Sumanta Monty, additional, and Chehrazi-Raffle, Alex, additional

Published
2023
Full Text
View/download PDF

23. Impact of race and payer status on the choice of urinary diversion among patients with localized bladder carcinoma undergoing cystectomy.

Author

Tripathi, Abhishek, primary, Barragan-Carrillo, Regina, additional, Philip, Errol James, additional, Govindarajan, Ameish, additional, Chawla, Neal, additional, Castro, Daniela V., additional, Chehrazi-Raffle, Alexander, additional, Dizman, Nazli, additional, Hsu, Joann, additional, Meza, Luis A, additional, Zengin, Zeynep Busra, additional, Bergerot, Cristiane Decat, additional, Eilber, Karyn, additional, Pal, Sumanta Monty, additional, and Dallas, Kai, additional

Published
2023
Full Text
View/download PDF

24. Improved health-related quality of life (HR-QOL) with use of an online mindfulness tool in patients with metastatic renal cell carcinoma (mRCC) receiving immunotherapy (IO).

Author

Bergerot, Cristiane Decat, primary, Malhotra, Jasnoor, additional, Bergerot, Paulo Gustavo, additional, Philip, Errol James, additional, Castro, Daniela V., additional, Govindarajan, Ameish, additional, Molina, Lorena Nascimento Manrique, additional, Fuzita, William Hiromi, additional, Azeredo, Andressa Cardoso, additional, Mota, Augusto C. A., additional, Franca, Marcos V S, additional, Anjos, Gabriel dos, additional, Filho, Romildo De Araujo Periera, additional, de Souza, Douglas Manfroi, additional, Hsu, Joann, additional, Chawla, Neal, additional, Chehrazi-Raffle, Alex, additional, Saab, Bechara, additional, Carlson, Linda E, additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

25. Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC).

Author

Barragan-Carrillo, Regina, primary, Dallas, Kai, additional, Tripathi, Abhishek, additional, Govindarajan, Ameish, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Philip, Errol James, additional, Castro, Daniela V., additional, Chehrazi-Raffle, Alexander, additional, Chawla, Neal, additional, Hsu, Joann, additional, Dizman, Nazli, additional, Eilber, Karyn, additional, Bergerot, Cristiane Decat, additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

26. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC).

Author

Chehrazi-Raffle, Alex, primary, Tukachinsky, Hanna, additional, Schrock, Alexa Betzig, additional, Hwang, Justin, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Chawla, Neal Shiv, additional, Ebrahimi, Hedyeh, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Rock, Adam, additional, Tripathi, Abhishek, additional, Dorff, Tanya B., additional, Pal, Sumanta Monty, additional, Oxnard, Geoffrey R., additional, Agarwal, Neeraj, additional, and Antonarakis, Emmanuel S., additional

Published
2023
Full Text
View/download PDF

27. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).

Author

Dizman, Nazli, primary, Govindarajan, Ameish, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Castro, Daniela V., additional, Chan, Elyse H., additional, Lee, Kyle O., additional, Prajapati, Sweta R., additional, Feng, Matthew I., additional, Loo, Vivian, additional, Pace, Makala, additional, O'brien, Shea, additional, Bailey, Erin B., additional, Barragan-Carrillo, Regina, additional, Chehrazi-Raffle, Alex, additional, Li, Xiaochen, additional, Agarwal, Neeraj, additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

28. Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC).

Author

Ebrahimi, Hedyeh, primary, Battle, Dena, additional, Zengin, Zeynep Busra, additional, Dizman, Nazli, additional, Meza, Luis A, additional, Castro, Daniela V., additional, Govindarajan, Ameish, additional, Mercier, Benjamin D., additional, Chawla, Neal Shiv, additional, Chehrazi-Raffle, Alex, additional, Tripathi, Abhishek, additional, Liu, Sandy, additional, Vaishampayan, Ulka N., additional, Staehler, Michael D., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

29. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.

Author

Feng, Matthew I., primary, Prajapati, Sweta R., additional, Castro, Daniela V., additional, Lee, Kyle O., additional, Chan, Elyse H., additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, O'Dell, Anna, additional, Zengin, Zeynep Busra, additional, Li, Xiaochen, additional, Chehrazi-Raffle, Alex, additional, Dizman, Nazli, additional, Tripathi, Abhishek, additional, Rock, Adam, additional, Liu, Sandy, additional, Mercier, Benjamin D., additional, Meza, Luis A, additional, Philip, Errol James, additional, Dorff, Tanya B., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

30. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.

Author

Castro, Daniela V., primary, Feng, Matthew I., additional, Prajapati, Sweta R., additional, Chan, Elyse H., additional, Lee, Kyle O., additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, O'Dell, Anna, additional, Zengin, Zeynep Busra, additional, Li, Xiaochen, additional, Chehrazi-Raffle, Alex, additional, Dizman, Nazli, additional, Tripathi, Abhishek, additional, Rock, Adam, additional, Liu, Sandy, additional, Mercier, Benjamin D., additional, Meza, Luis A, additional, Philip, Errol James, additional, Dorff, Tanya B., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

32. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma

Author

Zengin, Zeynep B., Govindarajan, Ameish, Salgia, Nicholas, Sayegh, Nicolas, Tripathi, Nishita, Muddasani, Ramya, Chehrazi-Raffle, Alex, Feng, Matthew, Mercier, Benjamin D., Ladbury, Colton, Hao, Claire, Salgia, Sabrina, Chawla, Neal, Meza, Luis, Malhotra, Jasnoor, Dizman, Nazli, Hsu, JoAnn, Castro, Daniela V., Barragan-Carrillo, Regina, Ebrahimi, Hedyeh, Philip, Errol J., Chang, Mark, Zhang, Jiaming, Byron, Sara, Lyou, Yung, Dorff, Tanya, Pal, Sumanta K., and Dandapani, Savita

Published
2023
Full Text
View/download PDF

33. Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study

Author

Castro, Daniela V., primary, Zengin, Zeynep B., additional, Malhotra, Jasnoor, additional, Bergerot, Cristiane D., additional, Meza, Luis, additional, Dizman, Nazli, additional, Govindarajan, Ameish, additional, Hsu, JoAnn, additional, Chehrazi-Raffle, Alex, additional, Chawla, Neal, additional, Mercier, Benjamin D., additional, Chen, Sean W., additional, Feng, Matthew, additional, Prajapati, Sweta, additional, Lee, Kyle O., additional, Philip, Errol J., additional, Dorff, Tanya B., additional, Lyou, Yung, additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

34. Abstract 6293: Genomic characteristics of nivolumab/ipilimumab with or without CBM-588 supplementation in patients with metastatic renal cell carcinoma

Author

Castro, Daniela V., primary, Dizman, Nazli, additional, Zengin, Zeynep B., additional, Malhotra, Jasnoor, additional, Meza, Luis A., additional, Muddasani, Ramya, additional, Govindarajan, Ameish, additional, Chawla, Neal S., additional, Chehrazi-Raffle, Alex, additional, Hsu, JoAnn, additional, Bergerot, Paulo G., additional, Bergerot, Cristiane D., additional, Dorff, Tanya B., additional, Lyou, Yung, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

35. Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.

Author

Dizman, Nazli, primary, Meza, Luis A, additional, Bergerot, Paulo Gustavo, additional, Dorff, Tanya B., additional, Lyou, Yung, additional, Frankel, Paul Henry, additional, Llamas, Marian, additional, Hsu, Joann, additional, Zengin, Zeynep Busra, additional, Malhotra, Jasnoor, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Gillece, John D, additional, Reining, Lauren J, additional, Trent, Jeffrey M., additional, Takahashi, Motomichi, additional, Oka, Kentaro, additional, Higashi, Seiya, additional, Highlander, Sarah K, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

36. A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).

Author

Meza, Luis A, primary, Malhotra, Jasnoor, additional, Zengin, Zeynep Busra, additional, Dizman, Nazli, additional, Hsu, Joann, additional, Chawla, Neal Shiv, additional, Chehrazi-Raffle, Alex, additional, Muddasani, Ramya, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Dorff, Tanya B., additional, Lyou, Yung, additional, Frankel, Paul Henry, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

37. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).

Author

Zengin, Zeynep Busra, primary, Govindarajan, Ameish, additional, Muddasani, Ramya, additional, Salgia, Nicholas, additional, Sayegh, Nicolas, additional, Tripathi, Nishita, additional, Salgia, Sabrina, additional, Meza, Luis A, additional, Zhang, Jiaming, additional, Chawla, Neal Shiv, additional, Chehrazi-Raffle, Alex, additional, Malhotra, Jasnoor, additional, Dizman, Nazli, additional, Hsu, Joann, additional, Castro, Daniela V., additional, Byron, Sara A., additional, Dandapani, Savita V., additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

39. Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).

Author

Meza, Luis A, primary, Choi, Yongwook, additional, Govindarajan, Ameish, additional, Dizman, Nazli, additional, Zengin, Zeynep Busra, additional, Hsu, Joann, additional, Salgia, Nicholas, additional, Salgia, Sabrina, additional, Malhotra, Jasnoor, additional, Chawla, Neal Shiv, additional, Chehrazi-Raffle, Alex, additional, Muddasani, Ramya, additional, Castro, Daniela V., additional, Chan, Agnes, additional, Zhang, Guangfa, additional, Byron, Sara A., additional, Highlander, Sarah K, additional, Schork, Nick, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

40. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.

Author

Muddasani, Ramya, primary, Govindarajan, Ameish, additional, Salgia, Sabrina, additional, Salgia, Nicholas, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Hsu, Joann, additional, Chehrazi-Raffle, Alex, additional, Dizman, Nazli, additional, Chawla, Neal Shiv, additional, Malhotra, Jasnoor, additional, Bergerot, Cristiane Decat, additional, Philip, Errol James, additional, Castro, Daniela V., additional, Dandapani, Savita V., additional, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

41. Prospective assessment of a smartphone-app based mindfulness program for patients with metastatic renal cell carcinoma (mRCC).

Author

Bergerot, Cristiane Decat, primary, Malhotra, Jasnoor, additional, Bergerot, Paulo Gustavo, additional, Philip, Errol James, additional, Govindarajan, Ameish, additional, Salgia, Sabrina, additional, Hsu, Joann, additional, Matos Neto, Joao Nunes, additional, Molina, Lorena Nascimento Manrique, additional, Vasconcellos, Vitor Fiorin de, additional, Muddasani, Ramya, additional, Chawla, Neal Shiv, additional, Castro, Daniela V., additional, Chehrazi-Raffle, Alex, additional, Saab, Bechara, additional, Carlson, Linda E, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

42. Characterization of aberrant alternative splicing landscape in patients with renal cell carcinoma (RCC).

Author

Govindarajan, Ameish, primary, Hegde, Apurva M., additional, Chawla, Neal Shiv, additional, Dizman, Nazli, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Muddasani, Ramya, additional, Chehrazi-Raffle, Alex, additional, Malhotra, Jasnoor, additional, Castro, Daniela V., additional, Salgia, Sabrina, additional, Bergerot, Cristiane Decat, additional, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Philip, Errol James, additional, Hsu, Joann, additional, Byron, Sara A., additional, Pirrotte, Patrick, additional, and Pal, Sumanta K., additional

Published
2022
Full Text
View/download PDF

43. Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity

Author

Park, Sang Ho, primary, Siddiqi, Haley, additional, Castro, Daniela V., additional, De Angelis, Anna, additional, Oom, Aaron L., additional, Stoneham, Charlotte A., additional, Lewinski, Mary K., additional, Clark, Alex E., additional, Croker, Ben A., additional, Carlin, Aaron F., additional, Guatelli, John, additional, and Opella, Stanley J., additional

Published
2021
Full Text
View/download PDF

44. Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.

Author

Ebrahimi, Hedyeh, Meza, Luis A., Lee, Keehoon, Malhotra, Jasnoor, Alcantara, Marice, Zengin, Zeynep Busra, Dizman, Nazli, Govindarajan, Ameish, Hsu, Joann, Llamas-Quitiquit, Marian, Chawla, Neal Shiv, Castro, Daniela V., Mercier, Benjamin D., Liu, Sandy, Chehrazi-Raffle, Alex, Dorff, Tanya B., Frankel, Paul Henry, Li, Xiaochen, Pal, Sumanta Kumar, and Tripathi, Abhishek

Published
2023
Full Text
View/download PDF

45. Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC).

Author

Meza, Luis A, Choi, Yongwook, Zhang, Jiaming, Dizman, Nazli, Zengin, Zeynep Busra, Ebrahimi, Hedyeh, Barragan-Carrillo, Regina, Hsu, Joann, Chawla, Neal Shiv, Chehrazi-Raffle, Alex, Tripathi, Abhishek, Castro, Daniela V., Mercier, Benjamin D, Govindarajan, Ameish, Chan, Agnes, Schork, Nicholas, Byron, Sara A., and Pal, Sumanta Kumar

Published
2023
Full Text
View/download PDF

46. Assessment of short-chain fatty acid (SCFA) and circulating cytokine trends in a clinical trial of nivolumab/ipilimumab and CBM588 in metastatic renal cell carcinoma (mRCC).

Author

Dizman, Nazli, Pathak, Khyatiben, Alcantara, Marice, Meza, Luis A, Bergerot, Paulo Gustavo, Willey, Maya, Dorff, Tanya B., Hsu, Joann, Zengin, Zeynep Busra, Castro, Daniela V., Ebrahimi, Hedyeh, Chehrazi-Raffle, Alex, Tripathi, Abhishek, Trent, Jeffrey M., Takahashi, Motomichi, Oka, Kentaro, Higashi, Seiya, Kortylewski, Marcin, Pirrotte, Patrick, and Pal, Sumanta Kumar

Published
2023
Full Text
View/download PDF

47. Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D.

Author

Bergerot, Cristiane Decat, Mercier, Benjamin D, Castro, Daniela V., Bergerot, Paulo Gustavo, Toms, Charlotte, Ali, Adil A, Philip, Errol James, Lages, Dr. Paulo Sergio, Mota, Augusto C. A., Hutson, Thomas E., Grünwald, Viktor, Bex, Axel, Psutka, Sarah P., Rini, Brian I., Plimack, Elizabeth R., Master, Viraj A., Albiges, Laurence, Choueiri, Toni K., Pal, Sumanta Kumar, and Powles, Thomas

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results